ProMIS Neurosciences doses first patients in Phase 1b PRECISE-AD trial of PMN310 for Alzheimer's disease

ProMIS Neurosciences Inc.

First patients dosed in Phase 1b PRECISE-AD trial evaluating PMN310, a humanized mAb targeting toxic Aβ oligomers.
Interim six-month results expected in 1H 2026; topline results anticipated in 2H 2026.
PMN310 selectively targets soluble amyloid-beta oligomers, avoiding monomers and plaques, potentially differentiating from current AD therapies.
Rapid enrollment underscores unmet need for better AD treatments; investigators note need for effective and well-tolerated options.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.